Free Trial

BuzzFeed (BZFD) Competitors

$2.41
-0.11 (-4.37%)
(As of 06/7/2024 ET)

BZFD vs. TOI, SLAM, SPIR, TSAT, MYNA, UCL, KORE, ANGH, MARK, and AYRO

Should you be buying BuzzFeed stock or one of its competitors? The main competitors of BuzzFeed include Oncology Institute (TOI), Slam (SLAM), Spire Global (SPIR), Telesat (TSAT), Mynaric (MYNA), uCloudlink Group (UCL), KORE Group (KORE), Anghami (ANGH), Remark (MARK), and Ayro (AYRO).

BuzzFeed vs.

Oncology Institute (NASDAQ:TOI) and BuzzFeed (NASDAQ:BZFD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation, community ranking and media sentiment.

Oncology Institute currently has a consensus target price of $2.25, suggesting a potential upside of 400.00%. Given BuzzFeed's higher possible upside, equities research analysts clearly believe Oncology Institute is more favorable than BuzzFeed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncology Institute
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
BuzzFeed
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Oncology Institute has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, BuzzFeed has a beta of 3.4, meaning that its stock price is 240% more volatile than the S&P 500.

Oncology Institute has higher revenue and earnings than BuzzFeed. BuzzFeed is trading at a lower price-to-earnings ratio than Oncology Institute, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncology Institute$324.24M0.10-$83.07M-$0.81-0.56
BuzzFeed$252.68M0.35-$88.58M-$2.46-0.98

Oncology Institute received 2 more outperform votes than BuzzFeed when rated by MarketBeat users. Likewise, 66.67% of users gave Oncology Institute an outperform vote while only 11.11% of users gave BuzzFeed an outperform vote.

CompanyUnderperformOutperform
Oncology InstituteOutperform Votes
4
66.67%
Underperform Votes
2
33.33%
BuzzFeedOutperform Votes
2
11.11%
Underperform Votes
16
88.89%

Oncology Institute has a net margin of -20.28% compared to Oncology Institute's net margin of -32.51%. Oncology Institute's return on equity of -58.08% beat BuzzFeed's return on equity.

Company Net Margins Return on Equity Return on Assets
Oncology Institute-20.28% -109.10% -32.26%
BuzzFeed -32.51%-58.08%-16.19%

36.9% of Oncology Institute shares are held by institutional investors. Comparatively, 37.6% of BuzzFeed shares are held by institutional investors. 9.5% of Oncology Institute shares are held by company insiders. Comparatively, 20.3% of BuzzFeed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, BuzzFeed had 5 more articles in the media than Oncology Institute. MarketBeat recorded 6 mentions for BuzzFeed and 1 mentions for Oncology Institute. BuzzFeed's average media sentiment score of 0.98 beat Oncology Institute's score of 0.55 indicating that Oncology Institute is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncology Institute
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BuzzFeed
3 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Oncology Institute beats BuzzFeed on 10 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BZFD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BZFD vs. The Competition

MetricBuzzFeedCommunication services IndustryDiscretionary SectorNASDAQ Exchange
Market Cap$88.23M$1.29B$6.82B$8.17B
Dividend YieldN/A5.15%2.81%4.04%
P/E Ratio-0.989.8915.5614.45
Price / Sales0.3511.295.8368.78
Price / CashN/A11.7838.4031.03
Price / Book0.793.905.374.32
Net Income-$88.58M-$289.77M$185.69M$216.21M
7 Day Performance-13.93%-3.70%-0.41%-1.44%
1 Month Performance30.98%14.15%2.94%-0.60%
1 Year Performance-6.95%-6.90%5.99%3.53%

BuzzFeed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TOI
Oncology Institute
2.7785 of 5 stars
$0.45
flat
$2.25
+400.0%
-6.2%$33.50M$342.71M-0.56800Gap Up
SLAM
Slam
0 of 5 stars
$11.07
flat
N/A+5.0%$259.63MN/A0.005Positive News
SPIR
Spire Global
2.528 of 5 stars
$10.17
+9.0%
$16.83
+65.5%
+61.3%$247.33M$105.70M-2.92407Analyst Forecast
TSAT
Telesat
0.8558 of 5 stars
$10.11
-2.0%
$9.00
-11.0%
+18.4%$137.60M$672.91M1.41N/ANews Coverage
Positive News
MYNA
Mynaric
0 of 5 stars
$4.71
+0.9%
N/A-30.2%$106.49M$5.39M0.00293Gap Up
UCL
uCloudlink Group
0 of 5 stars
$1.74
flat
N/A-55.4%$65.16M$85.58M58.00393Gap Down
KORE
KORE Group
2.2508 of 5 stars
$0.66
+8.3%
$2.94
+348.2%
-52.2%$54.58M$276.61M-0.35600Gap Down
ANGH
Anghami
0 of 5 stars
$1.08
flat
N/A-0.9%$32.09M$41.38M0.00143Positive News
MARK
Remark
0 of 5 stars
$0.13
flat
N/A-89.7%$6.01M$4.40M-0.0846Gap Up
AYRO
Ayro
0 of 5 stars
$0.90
-2.2%
N/A-84.9%$4.77M$500,000.00-0.1158Positive News
High Trading Volume

Related Companies and Tools

This page (NASDAQ:BZFD) was last updated on 6/8/2024 by MarketBeat.com Staff

From Our Partners